Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation.

ABSTRACT:

Background

Islet cell transplantation can cure type 1 diabetes (T1D), but only a minority of recipients remains insulin-independent in the following years. We tested the hypothesis that allograft rejection and recurrent autoimmunity contribute to this progressive loss of islet allograft function.

Methodology/principal findings

Twenty-one T1D patients received cultured islet cell grafts prepared from multiple donors and transplanted under anti-thymocyte globulin (ATG) induction and tacrolimus plus mycophenolate mofetil (MMF) maintenance immunosuppression. Immunity against auto- and alloantigens was measured before and during one year after transplantation. Cellular auto- and alloreactivity was assessed by lymphocyte stimulation tests against autoantigens and cytotoxic T lymph

SUBMITTER: Huurman VA 

PROVIDER: S-EPMC2426735 | biostudies-literature | 2008 Jun

REPOSITORIES: biostudies-literature